China Pharmacogenetic Testing in Psychiatry depression Market to 2032

Overview

The China Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 78.14 USD Billion by 2032 and is projected to grow at a CAGR of 17.36% from 2025 to 2032.

Revenue, 2024 (USD Billion)
33.90
Forecast, 2032 (USD Billion)
78.14
CAGR, 2024 - 2032
17.36%
Report Coverage
China

China Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion

China Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 33.90 USD Billion
  • Projected Market Size (2032): 78.14 USD Billion
  • CAGR (2025-2032): 17.36%

Key Findings of China Pharmacogenetic Testing in Psychiatry depression Market

  • The China Pharmacogenetic Testing in Psychiatry depression Market was valued at 33.90 USD Billion in 2024.
  • The China Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 17.36% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 22.39 USD Billion
  • The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 23.30% during the forecast period from 2024 to 2032.

China Pharmacogenetic Testing in Psychiatry depression Market Scope

China Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • Others
  • HLA-B
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Type
  • Array-Based Tests
  • Whole Genome Sequencing
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

China Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights

Study Period 2024-2032
Base Year 2020
Unit Revenue in USD Billion
Market Value in 2024 33.90 USD Billion
Market Value in 2032 78.14 USD Billion
CAGR (2025-2032) 17.36%
Historic Data 2016-2023
Market Segments Covered Application,Sample,Drug Type,End User,Genes,Type,Distribution Channel

Regional Insights:

  • Leading Market (2024-2032): China, leading in terms of revenue 33.90 USD Billion in 2024
    • Key Country: China, leading in terms of revenue with value of 33.90 USD Billion in 2024.

Segments and Scope

  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
    • Drug Development is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 18.54 USD Billion in the year 2024.
    • Drug Development is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 18.10 % in forecast period 2025-2032.
  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
    • Saliva is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 22.39 USD Billion in the year 2024.
    • Saliva is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.90 % in forecast period 2025-2032.
  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
    • Prescription Drugs is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 15.66 USD Billion in the year 2024.
    • Recreational Drugs is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.68 % in forecast period 2025-2032.
  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
    • Pharmaceutical & Biotechnology Companies is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 13.98 USD Billion in the year 2024.
    • Pharmaceutical & Biotechnology Companies is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 18.56 % in forecast period 2025-2032.
  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
    • CYP2C19 is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 8.26 USD Billion in the year 2024.
    • CYP2C19 is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 23.30 % in forecast period 2025-2032.
  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
    • Whole Genome Sequencing is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 21.03 USD Billion in the year 2024.
    • Whole Genome Sequencing is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.93 % in forecast period 2025-2032.
  • China Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
    • Retail Pharmacies is the largest segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 14.63 USD Billion in the year 2024.
    • Hospital Pharmacies is the Fastest growing segment in China Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 17.53 % in forecast period 2025-2032.

China Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

 
Company Name Company Share Analysis
Millennium Health
Myriad Genetics, Inc.
PerkinElmer Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.
China Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

China Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

China Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

China Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

China Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The China Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Application,Sample,Drug Type,End User,Genes,Type,Distribution Channel.
China Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 33.90(Revenue in USD Billion) in 2020.
China Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 17.36% during the forecast period of 2024 to 2032.
The Saliva segment is expected to dominate the China Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 22.39 USD Billion in 2024

China Pharmacogenetic Testing in Psychiatry depression Market Scope

China Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • Others
  • HLA-B
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Type
  • Array-Based Tests
  • Whole Genome Sequencing
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Frequently Asked Questions
The China Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Application,Sample,Drug Type,End User,Genes,Type,Distribution Channel.
China Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 33.90(Revenue in USD Billion) in 2020.
China Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 17.36% during the forecast period of 2024 to 2032.
The estimated market value of the China Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 78.14 (USD Billion).

China Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

China Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The China Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Application,Sample,Drug Type,End User,Genes,Type,Distribution Channel.
China Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 33.90(Revenue in USD Billion) in 2020.
China Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 17.36% during the forecast period of 2024 to 2032.
The estimated market value of the China Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 78.14 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.